ERBB2 and breast carcinoma: At high doses, apigenin was demonstrated to prevent theactivation of the estrogen receptor by 17β-estradiol and cause inhibitionof the HER2/neu expression, accompanied by a degradation of PARP inHER2-positive breast cancer cells.